Advertisement
UK markets closed
  • FTSE 100

    7,995.58
    +71.78 (+0.91%)
     
  • FTSE 250

    19,721.24
    -65.63 (-0.33%)
     
  • AIM

    755.91
    -2.92 (-0.38%)
     
  • GBP/EUR

    1.1694
    -0.0007 (-0.06%)
     
  • GBP/USD

    1.2451
    -0.0104 (-0.83%)
     
  • Bitcoin GBP

    51,833.91
    -2,319.44 (-4.28%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,123.41
    -75.65 (-1.46%)
     
  • DOW

    37,983.24
    -475.84 (-1.24%)
     
  • CRUDE OIL

    85.45
    +0.43 (+0.51%)
     
  • GOLD FUTURES

    2,360.20
    -12.50 (-0.53%)
     
  • NIKKEI 225

    39,523.55
    +80.92 (+0.21%)
     
  • HANG SENG

    16,721.69
    -373.34 (-2.18%)
     
  • DAX

    17,930.32
    -24.16 (-0.13%)
     
  • CAC 40

    8,010.83
    -12.91 (-0.16%)
     

Global $32.34 Billion Bioelectric Medicine Markets to 2030: Increasing Acceptance of Implantable Electroceutical Devices

Company Logo
Company Logo

Bioelectric Medicine Market

Bioelectric Medicine Market
Bioelectric Medicine Market

Dublin, May 03, 2023 (GLOBE NEWSWIRE) -- The "Global Bioelectric Medicine Market Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

The value of the bioelectric medicine market was USD 21,532.1 million in 2022, and it will power at a rate of 5.2% in the future, to touch USD 32,345.8 million by 2030

Implantable Cardioverter Defibrillators Are Most Used

Implantable cardioverter defibrillators are the most used of all the products, because of their extensive range of applications. Their electrical stimulation capability makes them necessary for the treatment of atrial fibrillation, ventricular tachycardia, and atrial flutter. Furthermore, they are employed in conjunction with other treatments, including medications or surgery.

ADVERTISEMENT

The increasing occurrence of cardiac arrests and neurological ailments in the elderly population is pushing the growth of this category. This part of society has a mounting requirement for implantable devices, including cardioverter defibrillators, deep-brain stimulators, cardiac pacemakers, and spinal cord stimulators.

Bioelectric Medicine Need Highest among Arrhythmia Patients

The arrhythmia category dominates the industry with around 60% of the revenue, and it will attain the highest CAGR in the future. This is because of the growing patient pool with the issue of arrhythmias, which widely uses implantable cardioverter defibrillators and cardiac pacemakers.

Moreover, several players are stressing over the increase of their business prospects, via collaborations, mergers, and partnerships, which will allow them to upgrade their research scope too.

Bioelectric Medicine Demand Is Highest in North America

North America had the largest revenue share, of above 40%, in the past, because of the high R&D investments, rising acceptance of technologically progressive devices, existence of major players, and large hospital count. Furthermore, the increasing healthcare spending is a key factor powering the regional industry.

Moreover, APAC will grow the fastest because of the increasing prevalence of numerous health ailments, including, Alzheimer's disease, epilepsy, spinal cord injuries, and cardiac arrhythmias; increasing government expenditure on the healthcare infrastructure, and wide accessibility of clinical labs and new diagnostic technologies.

Increasing Acceptance of Implantable Electroceutical Devices

The implantable electroceutical devices category had the largest share, of about 80%, in the past. This is mainly credited to the increasing prevalence of numerous cardiovascular and neurological illnesses and the increasing count of product approvals.

Hospitals To Grow Fastest as End Users

Hospitals will have the fastest growth, of around 7%, in the years to come. This will be because of the availability of cutting-edge devices for the detection and treatment of neurological and hearing ailments and skilled healthcare providers at these institutions.

Several chronic ailments, for example, Alzheimer's, arrhythmias, epilepsy, chronic pain, and retinitis pigmentosa, result in the hospitalization of the patient. In 2022, as per the Alzheimer's Association, about 6.5 million Americans aged over 65 years and about 73% of those aged 75 or more had Alzheimer's.

Key Attributes:

Report Attribute

Details

No. of Pages

240

Forecast Period

2022 - 2030

Estimated Market Value (USD) in 2022

$21532.1 Million

Forecasted Market Value (USD) by 2030

$32345.8 Million

Compound Annual Growth Rate

5.2%

Regions Covered

Global

Company Profiles

  • Medtronic plc

  • Abbott Laboratories

  • Boston Scientific Corporation

  • Livanova plc

  • Cochlear Limited

  • Nevro Corp.

  • Axonics Inc.

  • Second Sight Medical Products Inc.

  • Electrocore Inc.

  • Sonova Holding AG

  • Biowave Limited

  • Microport Scientific Corporation

  • Setpoint Medical Corporation

  • Sky Medical Technology

  • Neuronetics Inc.

For more information about this report visit https://www.researchandmarkets.com/r/7mcko

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900